Advice
following an abbreviated submission:
fosaprepitant dimeglumine (IVEmend 150mg®) is accepted for use within NHS Scotland.
Indication under review: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults.
IVEmend 150 mg is given as part of a combination therapy.
Fosaprepitant 150mg is not recommended for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults, as SMC has previously not recommended both fosaprepitant iv and aprepitant capsules for this indication.
Download detailed advice73KB (PDF)
Medicine details
- Medicine name:
- fosaprepitant (Ivemend)
- SMC ID:
- 678/11
- Indication:
- prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults. IVEmend 150 mg is given as part of a combination therapy.
- Pharmaceutical company
- MSD
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 March 2011